Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel Authors: Pedro Mendes-Bastos, Inês Lobo, Gilberto Pires da Rosa, Rita Pimenta, Margarida Gonçalo Published: 2026 ABSTRACT AbstractObjectiveChronic prurigo (CPG) is a chronic neuroinflammatory skin disease characterized by persistent itch, repeated scratching, and the presence of multiple skin lesions. CPG is a highly burdensome disease that significantly impairs patients’ quality of life. The objective of these consensus recommendations is to summarize available evidence and provide standardized guidance for the diagnosis and management of patients with CPG.MethodsThese recommendations were developed using a Delphi methodology, conducted over two rounds of online voting by the participation of 23 Portuguese dermatologists. The strength of consensus was defined as strong consensus (≥ 95% agreement), consensus (≥ 75%), and majority agreement (≥ 50%).ResultsThe diagnosis of CPG requires the concomitant presence of a ≥ 6-week history of pruritus; a history of repeated excoriation; and multiple skin lesions (including nodules, papules, umbilicated lesions, and linear lesions, among others). Diagnosis should be based on patient history and physical examination, and complemented by laboratory tests and additional investigations if needed. Treatment should follow a personalized protocol, according to disease severity and guided by both clinician- and patient-reported outcomes. Systemic therapeutic options for eligible patients include CPG-approved biological agents (dupilumab and nemolizumab), gabapentinoids, and antidepressants. Additional treatment options may be considered, including interleukin (IL)-13 inhibitors, Janus kinases (JAK) inhibitors, opioid receptor modulators, methotrexate, and cyclosporine. Treatment efficacy should be regularly assessed to ensure clinical improvement and patient adherence.ConclusionThis study provides guidance on the diagnosis and treatment of CPG supporting diagnosis and treatment decision-making.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13555-026-01766-2.Keywords: Chronic prurigo, Prurigo, Diagnosis, Therapeutics, Consensus Key Summary Points Historically, chronic prurigo (CPG) management relied on off-label therapies. However, recent advances in pathophysiological mechanisms and the approval of targeted treatments make evidence-based guidelines essential to guide and standardize practices.This study aimed to establish evidence-based recommendations to optimize the diagnosis and management of CPG following recent therapeutic advances.A panel of Portuguese dermatologists with experience in CPG management participated in a structured, two-round Delphi process to define expert consensus on practical recommendations for the diagnosis and treatment of CPG.Treatment of CPG should be personalized according to disease severity and patient-reported outcomes, with systemic options including CPG-approved biologics, and additional off-label therapies. Introduction Chronic prurigo (CPG), formerly known as prurigo nodularis (PN), is a chronic, neuroinflammatory skin disease characterized by intense pruritus and multiple localized or generalized scratch-associated skin lesions [1, 2]. Although the pathophysiology of CPG is not completely understood, current evidence indicates that both immune and neural mechanisms contribute to disease development. A predominant type 2-driven inflammatory response interacts with neuroinflammatory pathways, promoting neuronal plasticity and sensitization. Persistent itch and scratching further amplify this neuroimmune loop, sustaining the chronic itch–scratch cycle and lesion formation [3, 4]. Histologically, prurigo lesions show dermal fibrosis characterized by thickened and vertically oriented collagen fibers, an increased number of capillaries and fibroblasts, hypertrophic and hyperplastic nerve fibers, and a mixed inflammatory infiltrate composed of lymphocytes, macrophages, and eosinophils. Epidermal alterations are also characteristic and include hyperkeratosis with orthokeratosis or focal parakeratosis, hypergranulosis, acanthosis, and pseudoepitheliomatous hyperplasia [5–7]. The histopathologic findings in CPG are not invariably pathognomonic; however, they are frequently suggestive of the diagnosis and can assist in excluding other conditions with overlapping clinical features. CPG is a heterogeneous and multifactorial disease and is often associated with comorbid conditions of dermatological, systemic, neurological, or psychiatric origin [8, 9]. Patients with CPG have an impaired quality of life [10]. CPG may be underdiagnosed because of overlapping symptoms with other dermatological diseases. Recently, the terminology for CPG was standardized in Europe, and the first two therapeutic options for CPG have received approval. While European guidelines address CPG within the broader context of chronic pruritus, more focused guidance is needed. Therefore, the objective of these consensus recommendations is to summarize available evidence and provide dermatologists and other healthcare professionals with a standardized approach to the diagnosis and treatment of CPG. Epidemiology Data on the prevalence of CPG remain limited, and there are no estimates for the Portuguese population. The most recent data indicate that, in Europe, the prevalence of CPG ranges from 6.5 (Poland) [11] to 111.0 (Germany) [12] cases per 100,000. A recent study from Sweden reported a cumulative prevalence of severe PN of 22.8 per 100,000 [13] and, in the USA, the latest studies estimated a prevalence of 190 per 100,000 population [14]. The incidence ranges between 2.9 (England) [15] and 20 (Germany) [12, 16] per 100,000 person-years. Prevalence of CPG increases with age and is higher among female individuals, who have a threefold higher incidence than male individuals [14–16]. CPG is more frequent among individuals of African descent and less frequent among Asian and Hispanic populations [14]. Pathophysiology Pruritus originates from the activation of peripheral sensory neurons and C-fibers located in the epidermis and upper dermis that transmit pruritic signals [3]. Stimulation of sensory neurons through scratching leads to their activation and, consequently, to the release of neuropeptides such as substance P, nerve growth factor (NGF), and calcitonin gene-related peptide (CGRP) that activate immune cells and promote neurogenic inflammation [3, 5]. Substance P is a proinflammatory neuropeptide that acts on T cells, eosinophils, neutrophils, and mast cells namely by interacting with neurokinin-1 receptor (NK1R) [3, 5]. CGRP is also a proinflammatory neuropeptide that acts on eosinophils and mast cells, and can also influence endorphin levels, leading to the dysregulated expression of μ- and κ-opioid receptors [5]. Activation of immune cells by proinflammatory neuropeptides results in the release of inflammatory mediators, namely T helper 2 (Th2) cytokines such as interleukin (IL)-4, IL-13, IL-31, and IL-33, histamine, and prostaglandins, that play a major role in chronic pruritus, serving as a bridge between immune and neural dysregulation and perpetuating the inflammatory response [3, 5]. IL-31 is a neuroimmune cytokine that signals through the IL-31 receptor (IL-31R, composed of the IL-31Rα and Oncostatin M receptor beta [OSMRβ] subunits) present on peripheral sensory nerves, keratinocytes, and fibroblasts, activating JAK/STAT, PI3K/AKT, and MAPK pathways. These cascades promote itch, keratinocyte changes, inflammation, and fibrosis in the skin [17]. IL-4 and IL-13 directly activate sensory neurons and promote Th2 polarization, fibroblast proliferation, and release of pro-fibrotic mediators such as transforming growth factor beta (TGFβ) and collagen, collectively driving exaggerated tissue repair and skin fibrosis characteristic of CPG lesions [3, 5]. Other proinflammatory cytokines such as OSM, IL-22, and IL-17 are found at elevated concentrations in lesional skin of patients with CPG [18]. Comorbidities CPG is frequently associated with other comorbid conditions, namely atopic diseases, such as atopic dermatitis (AD), rhinitis, and asthma, or other dermatological diseases, such as psoriasis, cutaneous T cell lymphoma, lichen planus, and dermatitis herpetiformis [8, 9]. Additionally, CPG can be associated with cardiovascular, hepatic and kidney diseases, diabetes mellitus, neurological conditions (chronic pain), psychiatric disorders (depression and obsessive–compulsive disorder), hematological malignancies (non-Hodgkin and Hodgkin’s lymphoma), and infections (human immunodeficiency virus [HIV] and hepatitis B and C virus [HBV, HCV]) [9, 19, 20]. In a European cross-sectional study, 36% of participants reported comorbid conditions including atopic eczema (33%), rhinitis/conjunctivitis (29%), asthma (20%), heart disease (19%), depression (18%), diabetes (18%), lung disease (10%), kidney disease (7%), liver disease (6%), and cancer (4%) [10]. In another study from the USA, patients with CPG had higher rates of comorbidities, namely depression (54%), diabetes (43%), chronic kidney disease (29%), chronic obstructive pulmonary disease (COPD, 23%) congestive heart failure (20%), AD (16%), HIV infection (7%), and chronic hepatitis C (6%) [14]. Disease Burden Patients with CPG experience a substantial disease burden and an impaired quality of life. CPG negatively affects self-image, sleep quality, and both social and daily activities. In a cohort of 509 European patients with CPG, the majority reported moderate (40%) or severe (32%) intermittent or persistent itch, burning (40%), stinging (36%), and/or pain (33%) [10]. More than half of patients (53%) perceived that CPG had a negative impact on their daily lives, particularly by impairing mood (44%), sleep quality (43%), and interpersonal relationships (38%). Patients also show elevated rates of depression, a high prevalence of psychiatric comorbidities, and many reported missing work, school, or leisure activities [10, 21–23]. Comparative studies show that patients with CPG experience a superior disease burden and a more impaired quality of life than individuals with other dermatologic diseases [24]. In a European cohort of 552 patients with inflammatory dermatoses, those with PN (n = 69) reported significantly higher itch intensity (evaluated by the numeric rating scale [NRS]) and more severe quality-of-life impairment (Dermatology Life Quality Index [DLQI] and ItchyQoL) than patients with AD, contact dermatitis, psoriasis vulgaris, or lichen planus [25]. Methods The development of these recommendations was based on a Delphi methodology [26] and involved three phases: a literature search to identify clinically relevant questions with limited guidance or insufficient evidence; a meeting to define the Delphi questionnaire; and two rounds of voting. A scientific committee of five members (IL, GPR, MG, PMB, RP), all experienced in managing patients with CPG, was formed to support and advise throughout the Delphi process. Questionnaire Development For the literature review, studies were identified through database searches and selected by the scientific committee based on their relevance. Relevant publications included studies, case reports, case series, and reviews addressing the diagnosis and treatment of CPG (Supplementary Fig. S1). Based on this review, draft statements were formulated and discussed within the scientific committee. A total of 38 finalized statements were included in the Delphi questionnaire. Participants and Voting Rounds The Delphi panel consisted of Portuguese dermatologists with experience in CPG management, representing all regions of Portugal mainland, and the autonomous region of Azores. The participant dermatologists were identified by the scientific committee based on clinical expertise and availability, and their contributions were limited to independent professional opinions. Participants received an electronic invitation from the scientific committee for voting. The two voting rounds occurred between May and June 2025. Participants rated their level of agreement with each statement using a five-point Likert scale (1, strongly disagree; 2, disagree; 3, neither agree nor disagree; 4, agree; 5, strongly agree). Responses to all questions were mandatory. After each round, frequencies and percentage of agreement for each statement were calculated. Statements reaching ≥ 75% agreement (ratings 4–5) were considered consensus. Conversely, ≥ 75% disagreement (ratings 1–2) was considered negative consensus. Statements not reaching consensus in the first round were re-voted on in the second round. The Delphi process was monitored and analyzed by an external independent moderator. Following completion of the Delphi survey, the strength of consensus was established as strong consensus (≥ 95% agreement), consensus (≥ 75%), and majority agreement (≥ 50%). Ethical Approval This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The Delphi panel reflects only the opinions of participating experts who voluntarily completed the questionnaire. Consequently, ethical review or formal approval was not required. Participation in the Delphi panel was entirely voluntary and fully anonymized, and all participants provided informed consent regarding the handling and protection of their personal data prior to participation. Results and Discussion A total of 23 dermatologists participated in both rounds of the Delphi panel, representing 89% of all invited specialists. Of the 38 statements evaluated, 30 (79%) achieved consensus (≥ 75% agreement). Non-consensual statements were related to complementary exams performed at diagnosis (13%) and systemic therapies (8%) (Supplementary Table S1). Terminology For the diagnosis of chronic prurigo, it is necessary to have the concomitant presence of chronic pruritus (≥ 6 weeks), history and/or signs of repeated excoriation, and the localized or generalized presence of multiple pruritic lesions, namely nodules, and/or papules, and/or umbilicated lesions, and/or linear lesions (strong consensus, 100%). For the diagnosis of chronic prurigo, it is necessary to have the concomitant presence of chronic pruritus (≥ 6 weeks), history and/or signs of repeated excoriation, and the localized or generalized presence of multiple pruritic lesions, namely nodules, and/or papules, and/or umbilicated lesions, and/or linear lesions (strong consensus, 100%). For many years, the term prurigo was generally used to characterize different dermatologic conditions without a clear definition [1]. In 2018, the pruritus task force of the European Academy of Dermatology and Venereology (EADV) published an expert consensus defining the terminology and classification of CPG as a distinct disease [1]. In the USA, the terminology used to describe all variants is PN since it is considered sufficient and has an associated ICD-10 code (L28.1) [2]. According to the European definition, CPG is considered an “umbrella term” that includes different stages and manifestations of this disease, but requires the presence of pruritus as an initial sign and a neuronal sensitization through an itch–scratch cycle [1]. Pruriginous lesions, including papules, nodules, plaques, and umbilicated lesions, may coexist in the same patient or a monomorphic phenotype may occur [1]. Lesions can be excoriated, scaling, and/or crusted and are typically symmetrically distributed across scratching-accessible skin areas such as extensor surfaces of extremities, trunk, and back, generally without involvement of the face or palms [1, 24]. The “butterfly sign”, characterized by the sparing of the upper central back area that is inaccessible for scratching, is often present in patients with back involvement [19, 24]. Nevertheless, the butterfly sign may be less pronounced or absent if the patient uses instruments and tools to scratch areas inaccessible to manual scratching. Diagnosis During the patient’s anamnesis, it is important to characterize the pruritus, namely its duration, location, intensity, episodic or continuous nature, aggravating and relieving factors, and checking systemic symptoms such as night sweats, fever, weight loss, and fatigue (strong consensus, 100%). During the patient’s anamnesis, it is important to characterize the pruritus, namely its duration, location, intensity, episodic or continuous nature, aggravating and relieving factors, and checking systemic symptoms such as night sweats, fever, weight loss, and fatigue (strong consensus, 100%). In addition to the clinical examination, it is recommended to investigate potential concomitant pathologies, namely dermatological, systemic/metabolic, and neuropsychiatric (strong consensus, 100%). In addition to the clinical examination, it is recommended to investigate potential concomitant pathologies, namely dermatological, systemic/metabolic, and neuropsychiatric (strong consensus, 100%). The detailed clinical examination and patient medical history are essential for the diagnosis of CPG and to determine the possible etiology and guide clinical decision-making [2, 19]. Clinical examination should include inspection of the entire skin, including mucous membranes, scalp, nails, and anogenital region [27, 28]. The number and distribution of pruriginous lesions should be documented to assess disease severity and the percentage of excoriated lesions to evaluate disease activity [27]. Detailed information regarding patients’ pruritus, such as the onset, duration, intensity, quality, locations, and triggers, is important to determine underlying causes. Since the occurrence of CPG is often associated with different comorbid conditions, it is also essential to evaluate the patient’s medical history and medication use [19]. Additionally, the detailed physical examination, patient anamnesis, and medical history are important for the differential diagnosis from other dermatological conditions with similar manifestations (Fig. 1) [2, 19]. These include hypertrophic lichen planus, bullous pemphigoid, namely its variant pemphigoid nodularis, dermatitis herpetiformis, lichen amyloidosis, scabies, lupus erythematosus, multiple keratoacanthomas, AD, and psoriasis vulgaris [2, 19]. Initial laboratory workup for all chronic prurigo patients should include: Initial laboratory workup for all chronic prurigo patients should include: Complete blood count, blood glucose, creatinine, lactate dehydrogenase (LDH), transaminases, gamma-glutamyl transferase (GGT), alkaline phosphatase, bilirubin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), electrophoretic proteinogram, thyroid-stimulating hormone (TSH), and urinalysis (consensus, 75%). Complete blood count, blood glucose, creatinine, lactate dehydrogenase (LDH), transaminases, gamma-glutamyl transferase (GGT), alkaline phosphatase, bilirubin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), electrophoretic proteinogram, thyroid-stimulating hormone (TSH), and urinalysis (consensus, 75%). Viral serologies including HIV-1/2, HBV, and HCV (consensus, 79%). Viral serologies including HIV-1/2, HBV, and HCV (consensus, 79%). Diagnostic algorithm of chronic prurigo. Diagnosis is based on the obligatory presence of a ≥ 6-week history of pruritus, a history of repeated excoriation, and the presence of skin lesions (including nodules, papules, umbilicated lesions, and/or linear lesions). Diagnosis should be based on the patient’s anamnesis and physical examination, and complemented with laboratory tests or other exams as needed. After the diagnosis of chronic prurigo, the severity and burden of the disease should be assessed using validated scales. After diagnosis, treatment should be started according to disease severity in an individualized approach. CPG chronic prurigo, CRP C-reactive protein, DLQI Dermatology Life Quality Index, ESR erythrocyte sedimentation rate, GGT gamma-glutamyl transferase, HADS Hospital Anxiety and Depression Scale, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, IGA-PN/A/S Investigator Global Assessment for Prurigo Activity/Investigator Global Assessment for Prurigo Stage, IgE Immunoglobulin E, LDH lactate dehydrogenase, PAS Prurigo Activity Score, SD-NRS Sleep Disturbance Numerical Rating Scale, TSH thyroid-stimulating hormone, WI-NRS Worst-Itch Numeric Rating Scale Although the diagnosis of CPG is made by clinical examination and detailed medical history, the investigation of a potential underlying etiology is recommended [19]. Hence, an initial laboratory workup should be performed for all patients (Fig. 1). The prescription of laboratory tests may also support the differential diagnosis. The initial evaluation of serologies for HIV and HBV/HCV infection is not consensual among the different available guidelines. The SK2 guideline and the American consensus only recommend the laboratory analysis of viral serologies for suspected cases of hepatobiliary disease or HIV [2, 28], while the International Forum for the Study of Itch (IFSI) guideline recommends the initial screening of HBV/HCV serology, but HIV only in suspected cases [27]. It is known that HIV and HBC/HCV infections are a cause of CPG; however, the prevalence of HIV and HBV/HCV among patients with CPG is low [8, 20]. Nevertheless, different studies, including Portuguese retrospective studies, showed higher prevalences of CPG diagnosis among HIV-positive patients, particularly those with low CD4 counts, thus justifying initial testing [29, 30]. Depending on patients’ clinical history, physical exam, and initial tests, the following laboratory and imaging studies should be considered: Depending on patients’ clinical history, physical exam, and initial tests, the following laboratory and imaging studies should be considered: Total serum IgE (consensus, 83%). Total serum IgE (consensus, 83%). Chest X-ray (consensus, 75%). Chest X-ray (consensus, 75%). Abdominal ultrasound (consensus, 92%). Abdominal ultrasound (consensus, 92%). Skin biopsy (majority agreement, 73%). Skin biopsy (majority agreement, 73%). Hypersensitivity skin tests (strong consensus, 96%). Hypersensitivity skin tests (strong consensus, 96%). Further complementary exams may be prescribed depending on results from the initial diagnosis workup and in suspected cases (Fig. 1). Total serum IgE and hypersensitivity skin tests, such as prick and patch tests, should be performed in case of suspected allergy or autoimmune diseases. Additionally, anti-BP180 and anti-BP230 immunoassays can be requested in cases of clinical suspicion of bullous pemphigoid. Imaging techniques such as abdominal ultrasound and chest x-ray are helpful to exclude malignant causes of CPG, particularly in patients experiencing pruritus for less than 1 year [31]. Skin biopsy for histological and immunofluorescence analysis may be helpful in specific cases, particularly for the differential diagnosis from other skin diseases [31]. Standardized scales and questionnaires should be used to assess disease severity, namely Investigator Global Assessment Scale (IGA-PN/A; IGA-PN/S), and/or Worst Itch Numerical Rating Scale (WI-NRS), and/or Sleep Disturbance Numeric Rating Scale (SD-NRS), and/or Prurigo Activity and Severity Score (PAS) (consensus, 92%). Standardized scales and questionnaires should be used to assess disease severity, namely Investigator Global Assessment Scale (IGA-PN/A; IGA-PN/S), and/or Worst Itch Numerical Rating Scale (WI-NRS), and/or Sleep Disturbance Numeric Rating Scale (SD-NRS), and/or Prurigo Activity and Severity Score (PAS) (consensus, 92%). The documentation of disease severity should be performed at diagnosis. For that, different scales and questionnaires have been developed and validated. Disease severity can be evaluated using clinician-reported outcomes, namely the Investigator Global Assessment Scale for Activity (IGA-PN/A) and the Investigator Global Assessment Scale for Stage (IGA-PN/S) or the PAS [32]. While the IGA-PN/A assesses scratch activity by evaluating excoriations and crusts according to a five-point scale (0 to 4), the IGA-PN/S scores disease severity by quantifying the number of pruriginous lesions using the same five-point scale (0 to 4) [32]. The PAS is a seven-item scale that evaluates type, number, distribution type, distribution areas, exact number of lesions in the representative area, size, and activity [33]. Recently, a five-item version excluding the distribution type and lesion size items was validated [34]. Measuring itch intensity is fundamental since it is considered the highest burden of CPG. Nevertheless, pruritus intensity is a subjective measurement and should be assessed using patient-reported outcome measures that document the perception of intensity. This can be performed using the WI-NRS, a single-item NRS designed to measure the patients’ itch intensity in the previous 24 h using an 11-point rating scale (0 to 10) [35–37]. The impact of chronic prurigo on quality of life and mental health should be assessed using standardized scales, namely DLQI, and the Hospital Anxiety and Depression Scale (HADS) (consensus, 88%). The impact of chronic prurigo on quality of life and mental health should be assessed using standardized scales, namely DLQI, and the Hospital Anxiety and Depression Scale (HADS) (consensus, 88%). CPG profoundly impairs patients’ quality of life, with studies showing that it has a greater impact than other dermatological conditions such as acne, eczema, and psoriasis [22, 38]. The impact of the disease on patients’ quality of life can be measured using patient-reported outcomes such as the DLQI and the HADS. Although a more specific questionnaire for itch (ItchyQoL) exists, its length may limit its practicality for routine clinical consultations [39]. DLQI consists of 10 questions about six aspects of quality of life: symptoms and feelings, daily life activities, leisure, work and school, personal relationships, and treatment, whose responses can be scored from 0 (no impact) to 3 (maximum impact). The final score classifies the impact of dermatological disease on patients’ quality of life according to different categories: 0–1, no effect; 2–5, small effect; 6–10, moderate effect; 11–20, very large effect; 21–30, extremely large effect [40]. Since patients with CPG often suffer from depression and anxiety, HADS is also recommended. HADS includes two dimensions, anxiety and depression, each containing seven items scored from 0 to 3. For each dimension, a score ranging from 0 to 7 is considered normal, from 8 to 10 a borderline abnormal case, and from 11 to 21 an abnormal case that needs further examination or treatment [41]. Treatment An individualized therapeutic approach should be taken according to disease severity and its impact on quality of life, considering the patient’s psychological profile and comorbidities/concomitant therapies (strong consensus, 100%). An individualized therapeutic approach should be taken according to disease severity and its impact on quality of life, considering the patient’s psychological profile and comorbidities/concomitant therapies (strong consensus, 100%). Therapies for CPG include topical agents (such as emollients, corticosteroids, and topical calcineurin inhibitors), phototherapy, and systemic therapies (including conventional immunosuppressants, anti-H1 antihistamines, neuromodulating therapies, and immunomodulating therapies) (Fig. 2) [24]. The therapeutic approach should be guided by the severity of CPG and tailored to each patient’s individual characteristics. Therefore, age, comorbidities, concomitant medication, disease impact on quality of life, and patients’ preferences should be taken into consideration. Furthermore, since treatments for CPG often extend over prolonged periods, the potential long-term effects of medications should be carefully considered and discussed with patients [28]. Treatment of chronic prurigo. Emollients should be used consistently throughout treatment as baseline therapy. For cases of mild to moderate prurigo, topical calcineurin inhibitors, topical corticosteroids, intralesional corticosteroids injection, courses of phototherapy, and anti-H1 antihistamines may be considered. Other systemic therapies should be initiated in patients with high disease severity and/or high disease burden. Add-on therapies may be considered, if necessary, such as the combined administration of topical and systemic treatments, short courses of topical, systemic, or intralesional corticosteroids, and complementary phototherapy. DLQI Dermatology Life Quality Index, H1 histamine H1 receptor, IGA-PN/A/S Investigator Global Assessment Scale for Prurigo Activity/Stage, IL-13 interleukin-13, JAK Janus kinase, WI-NRS Worst Itch Numeric Rating Scale Emollients should be considered in all patients and at all treatment stages (consensus, 92%). Emollients should be considered in all patients and at all treatment stages (consensus, 92%). Increased transepidermal water loss due to decreased barrier function was identified as a good biomarker for itch intensity in patients with AD [42]. Therefore, emollients that support the maintenance of the epidermal barrier integrity are important adjuvant treatments that should be used in combination with other systemic therapies or topical agents. Formulations containing urea (10%) [43, 44], glycerol (15–20%) [43, 45–47], N-palmitoylethanolamine (PEA, 0.3%) [48, 49], and lipids [50, 51] have shown positive effects on improving skin hydration, restoring the skin barrier, and reducing itch in patients with AD, eczema, and xerosis and may also be beneficial for patients with CPG. Topical emollients are recommended as supportive background therapy in CPG, largely based on pathophysiological rationale and evidence extrapolated from xerosis and AD, rather than from robust CPG-specific clinical trials. Topical corticosteroids and topical calcineurin inhibitors should be considered in all patients (consensus, 92%). Topical corticosteroids and topical calcineurin inhibitors should be considered in all patients (consensus, 92%). Topical corticosteroids are frequently the first-line therapy for inflammatory skin diseases [28]. Nevertheless, the antipruritic effect of topical corticosteroids is attributed to an indirect consequence of their anti-inflammatory effects, and data supporting their use in CPG are predominantly based on case reports and randomized clinical trials (RCTs) with a small number of participants [52–54]. In a phase II RCT, treatment with 1% hydrocortisone significantly reduced pruritus intensity after a treatment period of 10 days [54]. Medium- to high-potency topical corticosteroids may be applied in areas of the trunk and extremities, while only low-potency agents should be used on the face and intertriginous areas. The long-term application of topical corticosteroids should be avoided due to the risk of local side effects and systemic absorption [55]. Topical calcineurin inhibitors, including tacrolimus (0.1%) and pimecrolimus (1%), have shown antipruritic effects in small cohorts of patients with CPG [54, 56, 57]. Nevertheless, the use of topical calcineurin inhibitors in CPG is currently off-label, and should not be combined with phototherapy. Intralesional corticosteroid therapy may be used in localized or refractory lesions (consensus, 87%). Intralesional corticosteroid therapy may be used in localized or refractory lesions (consensus, 87%). Intralesional therapy allows the injection of a higher drug concentration directly into the skin lesions [58]. The injection of triamcinolone acetonide (10 mg/ml) and lidocaine 0.75% combined with cryosurgery has previously been reported in patients with CPG [59]. Nevertheless, intralesional corticosteroid therapy should be limited to patients with few CPG lesions. Phototherapy may be considered in the treatment of chronic prurigo (strong consensus, 96%). Phototherapy may be considered in the treatment of chronic prurigo (strong consensus, 96%). Phototherapy for CPG includes broad-band ultraviolet (UV) A, narrowband UVB (NBUVB), and psoralen plus UVA (PUVA). UV therapy reduces the pruritus of many dermatological diseases, including CPG, by anti-inflammatory and neuromodulatory effects that interrupt the itch–scratch cycle. In a retrospective cohort study including 44 patients with CPG who received UVB or UVA + UVB phototherapy, 55% achieved a satisfactory response, defined as resolution of ≥ 75% of lesions [60]. In another study with 30 patients with CPG, NBUVB therapy resulted in 80% of complete responses (> 90% skin clearance) [61]. Erythema and itching were the most common side effects in both studies. Other studies and case series have also shown a satisfactory response of CPG lesions to phototherapy [62–64]. Nevertheless, most of the available evidence is based on small cohorts and non-randomized clinical trials. Non-sedating anti-H1antihistamines may be considered as an add-on therapy (consensus, 80%). Non-sedating anti-H1antihistamines may be considered as an add-on therapy (consensus, 80%). Non-sedating, second-generation antihistamines, including bilastine, cetirizine, levocetirizine, loratadine, desloratadine, and fexofenadine, are highly specific to the H1 receptor, thus having minimal sedative effect and prolonged action relative to their first-generation counterparts [65]. Non-sedating anti-H1 antihistamines are effective in blocking the acute cutaneous itch associated with mast cell degranulation, such as urticaria, but have limited effects in CPG [65]. The administration of bilastine 20 mg daily showed moderate results in reducing the itch of patients with CPG in small cohort studies and its use is off-label [66, 67]. Therefore, the use of non-sedating anti-H1 antihistamines in CPG should only be used in combination with other therapies. Short courses of systemic corticosteroids may be considered only in exceptional cases and situations (consensus, 92%). Short courses of systemic corticosteroids may be considered only in exceptional cases and situations (consensus, 92%). Systemic corticosteroids, used as off-label therapy in CPG, should be reserved for short-course treatment (no longer than 2 weeks) in cases of severe or refractory CPG, due to the risk of adverse events (AEs). Systemic therapy should be considered in patients with chronic prurigo who meet at least one of the following criteria: IGA-PN/A; IGA-PN/S ≥ 3; OR WI-NRS ≥ 7; OR DLQI ≥ 10 (strong consensus, 100%). Systemic therapy should be considered in patients with chronic prurigo who meet at least one of the following criteria: IGA-PN/A; IGA-PN/S ≥ 3; OR WI-NRS ≥ 7; OR DLQI ≥ 10 (strong consensus, 100%). Topical treatments for CPG often show only limited efficacy, particularly in patients with high disease burden. Therefore, systemic treatment is frequently needed and should be considered in patients presenting at least one of the criteria mentioned above. Most systemic therapies used for the treatment of CPG are prescribed off-label, including immunosuppressants (cyclosporine and methotrexate), antihistamines, gabapentinoids, opioid receptor modulators, antidepressants, anti-IL-13 monoclonal antibodies, and Janus kinase (JAK) inhibitors, with their use supported only by limited data [28]. Recent advances in understanding CPG pathophysiology have allowed the development of targeted therapies, offering more effective disease management. Currently, dupilumab and nemolizumab are the only approved systemic therapies for CPG. In Portugal, dupilumab for prurigo has been reimbursed in Portugal in January 2025, whereas nemolizumab is currently neither available nor reimbursed. Methotrexate may be considered in the treatment of chronic prurigo (consensus, 75%). Methotrexate may be considered in the treatment of chronic prurigo (consensus, 75%). Methotrexate is a immunomodulatory drug presenting anti-inflammatory activity used in the treatment of other inflammatory skin diseases, such as AD and psoriasis [68]. The efficacy and safety of methotrexate in the treatment of CPG were assessed in two retrospective studies, totaling 47 patients. Weekly administration of methotrexate (5–25 mg) resulted in an overall response rate (ORR) of 94% (n = 39) [68] and a > 75% reduction in the pruritus NRS (n = 13) [69] at 6 months after treatment initiation. The most frequently reported AEs included nausea and grade I transaminase elevation [68, 69]. Cyclosporine may be considered in the treatment of chronic prurigo (majority agreement, 66%). Cyclosporine may be considered in the treatment of chronic prurigo (majority agreement, 66%). Cyclosporine is a calcineurin inhibitor blocking IL-2 expression and signaling [70]. In a small single-center study of 14 patients with refractory CPG, oral cyclosporine (3–5 mg/kg daily) produced very good responses (80–100% reduction in the visual analogue scale [VAS] score) in 71% of patients and good responses (40–70% VAS reduction) in 21% [70]. The best antipruritic effect was registered in patients with atopic disposition [70]. In a retrospective study including eight patients who received 2–4 mg/kg of cyclosporine, six achieved disease remission after an average of 3 weeks [71]. For both studies, reported AEs included gastric upset, embolism, hypertension, creatinine elevation, angioedema, muscle pain, gingival hyperplasia, nausea, blurry vision, keratoacanthoma, hypercholesterolemia, and folliculitis [70, 71]. In the CPG population, drug–drug interactions and the presence of comorbid diseases may limit the use of cyclosporine. Based on current evidence, thalidomide and lenalidomide should not be considered in the treatment of chronic prurigo (majority agreement, 70%). Based on current evidence, thalidomide and lenalidomide should not be considered in the treatment of chronic prurigo (majority agreement, 70%). Thalidomide is an immunosuppressive drug that has an antipruritic effect by blocking tumour necrosis factor alpha (TNFα) and other proinflammatory cytokines, among other proposed mechanisms [72]. Treatment with thalidomide (50–300 mg daily) showed moderate to significant clinical improvements in small retrospective studies [73–76]. However, in all the mentioned studies, treatment discontinuation due to peripheral neuropathy and sedation was frequent. Accordingly, the use of thalidomide is related to severe side effects, including sedation, constipation, and severe teratogenicity during pregnancy; therefore, strict pregnancy prevention measures are mandatory [72]. Lenalidomide is a more potent analogue of thalidomide with a different toxicity profile, rendering a lower frequency of severe side effects [72]. Nevertheless, its efficacy in CPG was only evaluated in a few case reports [77, 78]. Gabapentinoids (gabapentin and pregabalin) should be considered in the treatment of chronic prurigo (strong consensus, 96%). Gabapentinoids (gabapentin and pregabalin) should be considered in the treatment of chronic prurigo (strong consensus, 96%). Gabapentin and pregabalin have demonstrated efficacy in reducing itch by binding to the α2δ subunit of voltage-gated calcium channels, thereby reducing the release of excitatory neurotransmitters and dampening central sensitization [79, 80]. Nevertheless, pregabalin is absorbed more rapidly and is associated with fewer side effects. The treatment of 30 patients with pregabalin 75 mg daily for 3 months resulted in the disappearance of pruritus, 76% nodule reduction, and a significant difference in the VAS scores [79]. In another study, four patients who received gabapentin at an increasing dosage (300, 600, and 900 mg/day) showed at least partial remission after 2 months of treatment [80]. Both pregabalin and gabapentin were well tolerated with few AEs that included sedation, dizziness, and headache [79, 80]. Antidepressants (such as paroxetine, mirtazapine, and doxepin) should be considered in the treatment of chronic prurigo (consensus, 87%). Antidepressants (such as paroxetine, mirtazapine, and doxepin) should be considered in the treatment of chronic prurigo (consensus, 87%). Tricyclic and tetracyclic antidepressants as well as serotonin reuptake inhibitors act by increasing serotonin level in the synaptic cleft. In an open-label RCT, 72 patients with severe CPG received either paroxetine (10–40 mg) or fluvoxamine (25–150 mg). Forty-nine patients (68%) responded to treatment, with more than half presenting good or very good responses (31–100% reduction in pruritus evaluated by the VAS score) [81]. The occurrence of AEs was frequent, with 71% of patients experiencing at least one AE [81]. Opioid receptor modulators (such as naltrexone and naloxone) may be considered in the treatment of chronic prurigo (consensus, 75%). Opioid receptor modulators (such as naltrexone and naloxone) may be considered in the treatment of chronic prurigo (consensus, 75%). Imbalances in the μ- and κ-opioid receptor systems affect pruritus, which is the rationale for using these medications for the treatment of CPG. While activation of μ-opioid receptors activates itch, the activation of κ-opioid receptors inhibits itch [82]. The efficacy of nalbuphine extended release (NAL-ER), a κ-opioid agonist and μ-opioid antagonist, was tested in a phase II RCT (n = 50) [82]. Treatment with 162 mg twice daily of NAL-ER resulted in a significantly superior antipruritic effect (WI-NRS reduction) at week 10 compared to placebo. Additionally, sustained benefit was observed in a group of patients who entered an extension trial and continued treatment up to 1 year. In the same trial, treatment with 81 mg of NAL-ER twice-daily failed to show superiority compared to placebo. Safety events included nausea, dizziness, headache, and fatigue [82]. Evidence from other opioid receptor modulators, namely naltrexone 50–150 mg, is provided by small non-placebo-controlled trials of patients with generalized pruritus showing response rates of 65–70% [83–85]. The antipruritic effect of naloxone infusions was tested in patients with cholestatic pruritus with significant improvements in the mean VAS score, compared to placebo [86, 87]. Based on the current evidence, NK1R antagonists (aprepitant and serlopitant) should not be considered in the treatment of chronic prurigo (majority agreement, 69%). Based on the current evidence, NK1R antagonists (aprepitant and serlopitant) should not be considered in the treatment of chronic prurigo (majority agreement, 69%). Substance P and its receptor, NK1R, play important roles in peripheral and central transmission of pruritus, justifying the rationale of developing NK1R antagonists for the treatment of CPG [88]. However, RCTs failed to demonstrate a clinical benefit of serlopitant and aprepitant. Initially, in a phase II RCT (n = 128), serlopitant 5 mg daily demonstrated a significantly greater reduction in pruritus (mean VAS score and pruritus NRS) compared to placebo at weeks 4 and 8 [88]. Nevertheless, in further phase III trials (n = 285; n = 295), the same treatment regimen failed to demonstrate significant superiority (improvement in WI-NRS) compared to placebo [89]. Treatment with aprepitant (80 mg daily), another NK1R inhibitor, also showed no superiority in the improvement of itch intensity, prurigo lesions, and quality of life of patients compared to placebo (n = 58) [90]. Therefore, given the absence of meaningful clinical improvements in patients with CPG, the use of NK1R antagonists is not recommended. Tralokinumab and/or lebrikizumab (anti-IL-13) may be considered in the treatment of chronic prurigo (strong consensus, 96%). Tralokinumab and/or lebrikizumab (anti-IL-13) may be considered in the treatment of chronic prurigo (strong consensus, 96%). Both tralokinumab (300 mg every 2 weeks) and lebrikizumab (250 mg every 2 weeks), two anti-IL-13 monoclonal antibodies, have shown a rapid reduction in pruritus in adults with moderate to severe AD [91–93]. In the ADvocate1 and ADvocate2 phase III RCTs of lebrikizumab monotherapy for patients with moderate to severe AD, a significantly higher proportion of patients treated with lebrikizumab achieved a ≥ 4-point improvement in pruritus NRS score at week 16 compared with those receiving placebo [93]. Tralokinumab also showed early improvements in pruritus of patients with AD in the ECZTRA 1 and 2 trials [92]. Additionally, tralokinumab demonstrated efficacy in the treatment of patients with AD presenting a CPG-like phenotype who had previously relapsed after dupilumab treatment (n = 77) [94]. For both lebrikizumab and tralokinumab, the most frequent AEs were adverse ocular events, injection-site reactions, and psoriasiform reactions [91, 92, 94]. Although both tralokinumab and lebrikizumab show potential for treating patients with CPG, no clinical data regarding their use in CPG are currently available, and further studies specifically targeting patients with CPG are needed. Despite the high consensus for the off-label use of IL-13 antagonists, this recommendation is based on limited and largely indirect evidence and should be interpreted as conditional. JAK inhibitors may be considered in the treatment of chronic prurigo (consensus, 92%). JAK inhibitors may be considered in the treatment of chronic prurigo (consensus, 92%). JAK inhibitors are small molecules that target and inhibit members of the JAK family—intracellular tyrosine kinases—thereby blocking the JAK/STAT signaling pathway [95]. The efficacy of abrocitinib, a JAK1 inhibitor, in the treatment of patients with CPG was tested in a non-randomized phase II clinical trial (n = 20) [96]. Treatment with abrocitinib 200 mg daily resulted in a mean reduction in pruritus NRS scores of 78% in patients with PN and 58% in those with chronic pruritus of unknown origin at week 12, complemented by a significant improvement in quality of life as measured by DLQI scores [96]. Abrocitinib was generally well tolerated, and the most common AEs included acneiform eruption, headache, and nausea. No serious AEs or treatment discontinuation due to safety reasons were reported [96]. Another JAK1 inhibitor, povorcitinib, has demonstrated efficacy in the treatment of patients with CPG in a phase II RCT (n = 146) [97]. At week 16, 36% (15 mg), 44% (45 mg), and 57% (75 mg) of patients achieved a ≥ 4-point improvement in WI-NRS. These results were sustained throughout the 40-week extension period, and 48% of initial placebo non-responders who switched to povorcitinib 75 mg during the extension achieved a therapeutic response [97]. Treatment was generally well tolerated with minimal grade ≥ 3 serious AEs and no new safety concerns in the extension trial [97]. Upadacitinib, a selective JAK1 inhibitor, showed promising results in the treatment of patients with CPG in a prospective cohort study (n = 10; 15 mg for 24 weeks) [98] and in a retrospective multicenter case series (n = 21; 15 mg for 52 weeks) [99]. In a recent systematic literature review of 211 patients with CPG treated with JAK inhibitors (upadacitinib, n = 80; tofacitinib, n = 62; abrocitinib, n = 41; and baricitinib, n = 28), 77% achieved clinically meaningful improvement, defined by a ≥ 4-point reduction in pruritus NRS, a IGA score of 0–1, or a ≥ 75% reduction in Pruritus Grading System Score (PGSS) [100]. JAK inhibitors carry a black box warning due to their association with serious infections, major adverse cardiovascular events, thrombosis, and malignancy. These safety concerns largely result from studies of tofacitinib in patients with rheumatoid arthritis (RA) [101]. While individuals with dermatological conditions are generally younger and have fewer comorbidities than those with RA, these risks remain relevant for patients with CPG, particularly older individuals and those presenting with multiple comorbidities. Despite the high consensus for the off-label use of JAK inhibitors, this recommendation is based on limited evidence and should be interpreted as conditional. Nemolizumab (anti-IL-31R) should be considered in the treatment of chronic prurigo (strong consensus, 96%). Nemolizumab (anti-IL-31R) should be considered in the treatment of chronic prurigo (strong consensus, 96%). Nemolizumab is a humanized monoclonal antibody that binds to IL-31Rα, competitively blocking the binding of IL-31 and preventing downstream signaling [17]. Nemolizumab received European Medicines Agency (EMA) approval for the treatment of adults with moderate to severe CPG and also for the treatment of moderate to severe AD (patients aged ≥ 12 years) [102]. Approval was based on the results from the phase III RCTs OLYMPIA 1 (n = 286) [103] and OLYMPIA 2 (n = 274) [104]. Patients treated with nemolizumab monotherapy (30 mg or 60 mg every 4 weeks, depending on baseline weight) demonstrated significant improvements in pruritus, defined as a ≥ 4-point reduction on the pruritus NRS. At week 16, 58% and 56% of patients achieved this response in OLYMPIA 1 and OLYMPIA 2, respectively, compared with 17% and 20% in the placebo groups. Similarly, IGA responses (score 0/1 with ≥ 2-point reduction) were observed in 26% and 38% of patients at week 16 (OLYMPIA 1 and OLYMPIA 2, respectively) and 31% at week 24 (OLYMPIA 1), compared with 7%, 11%, and 9% in the corresponding placebo groups [103, 104]. A rapid itch response was observed with significant differences between nemolizumab and placebo registered since week 4. Additionally, nemolizumab treatment showed significant superiority across all secondary endpoints, including itch response at week 4, itch-free state (pruritus NRS score < 2), improvement in skin nodules, and higher improvements in patient-reported outcomes [103, 104]. In the OLYMPIA 1 and 2 trials, most reported AEs were of mild or moderate severity and included headache, AD, eczema, asthma, and peripheral edema [103, 104]. Recently, in a Japanese phase II/III RCT (n = 226), nemolizumab treatment resulted in a pruritus NRS reduction superior to 75% at week 68, demonstrating the long-term efficacy of nemolizumab treatment in CPG without new safety concerns [105]. Dupilumab (anti-IL-4Rα) should be considered in the treatment of chronic prurigo (strong consensus, 100%). Dupilumab (anti-IL-4Rα) should be considered in the treatment of chronic prurigo (strong consensus, 100%). Dupilumab is a fully human monoclonal antibody targeting IL-4 receptor alpha (IL-4Rα), a receptor shared by IL-4 and IL-13, thus inhibiting Th2-mediated inflammation [106]. Dupilumab was the first systemic therapy approved by the EMA for the treatment of adult patients with CPG, and is also approved for moderate to severe AD (patients aged ≥ 6 months), severe asthma (patients aged ≥ 6 years), COPD, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis (patients aged ≥ 1 year), and chronic spontaneous urticaria (patients aged ≥ 12 years) [107]. For CPG, approval was based on the results of phase III RCTs PRIME (n = 151) and PRIME2 (n = 160) [108]. Patients treated with dupilumab (300 mg every 2 weeks) demonstrated significant improvement in pruritus (≥ 4-point improvement on the pruritus NRS score) at weeks 12 (37%, PRIME2) and 24 (60%, PRIME) compared with the placebo group (22% and 18%, respectively) [108]. Dupilumab was also significantly superior to placebo in improving skin lesions: 48% (PRIME) and 45% (PRIME2) of patients in the dupilumab groups achieved an IGA PN-S score of 0 or 1, compared to 18% (PRIME) and 16% (PRIME2) in the placebo group, regardless of atopic comorbidities [108, 109]. Additionally, dupilumab treatment led to a significantly higher proportion of patients achieving clinically meaningful improvements in patient-reported outcomes [110]. The efficacy of dupilumab in the treatment of patients with CPG beyond 24 weeks has been evaluated in real-world studies [111–115]. A 4-point reduction on the pruritus NRS was achieved by 100% of patients at week 84 (n = 16) [112] and by 97% of patients at week 104 (n = 64) [111]; and in another study, a subset of patients was able to discontinue the drug with no further recurrence [115]. Dupilumab showed a favorable safety profile, and registered treatment AEs included conjunctivitis and herpes infections [108]. Combined therapies should be considered in selected cases (strong consensus, 100%). Combined therapies should be considered in selected cases (strong consensus, 100%). Treatment of CPG often requires a multimodal approach, such as the concomitant use of topical and systemic therapies. Emollients should always be used during CPG treatment to support skin hydration. Short courses of topical, systemic, and intralesional corticosteroids may be combined with other systemic therapies in cases of high disease burden. Phototherapy can also be used as a complementary therapy (Fig. 2). The assessment of treatment response should be performed in a multifactorial manner and include the use of standardized scales, namely clinician-reported outcomes (e.g., IGA-PN/A, IGA-PN/S), and subjective scales, namely patient-reported outcomes (e.g., Prurigo Control Test [PCT], WI-NRS) (strong consensus, 96%). The assessment of treatment response should be performed in a multifactorial manner and include the use of standardized scales, namely clinician-reported outcomes (e.g., IGA-PN/A, IGA-PN/S), and subjective scales, namely patient-reported outcomes (e.g., Prurigo Control Test [PCT], WI-NRS) (strong consensus, 96%). Assessing treatment responses is essential to evaluate effectiveness and to guide decisions regarding the maintenance, optimization, or switching of therapy. Standardized clinician- and patient-reported outcomes scales should be used for this purpose. In the RCTs of both dupilumab and nemolizumab, primary treatment endpoints included a reduction of ≥ 4 points on the PP/WI-NR [104, 108]. Nemolizumab OLYMPIA trials also included an IGA response (a score of 0 or 1 and a reduction of ≥ 2 points from baseline) as the primary treatment endpoint [103, 104]. Secondary endpoints of CPG trials included sleep disturbance, pain frequency and intensity, health-related quality of life (assessed by the DLQI and EuroQoL Group 5-Dimensions [EQ-5D] questionnaire), and symptoms of anxiety and depression (assessed by the HADS scale) [103, 104, 108]. Future Perspectives The diagnosis and treatment of CPG have progressed from being a poorly understood skin disorder with limited treatment approaches to a well-characterized disease entity with recognized immunologic and neurologic components. This evolution, together with the increasing knowledge about the pathophysiology of CPG, has enabled the development of modern targeted therapies. Studies evaluating treatment patterns in patients with CPG revealed that the most frequently used therapies were topical corticosteroids, anti-H1 antihistamines, systemic glucocorticoids, and methotrexate, including in patients with severe disease [13, 116, 117]. With the approval of targeted therapies, however, a paradigm shift in management is expected in the upcoming years. Currently, dupilumab and nemolizumab are the only approved drugs for the treatment of patients with CPG, while several new agents are currently under investigation. Vixarelimab, a monoclonal antibody that inhibits OSM and IL-31 signaling by binding to OSMRβ, demonstrated a rapid decrease in pruritus intensity (measured by PP-NRS and WI-NRS), with a substantially higher proportion of participants achieving clinically meaningful improvement (≥ 4-point reduction in WI-NRS) and a good improvement of skin lesions (evaluated by the IGA score) in two phase II RCTs (n = 240) of PN [118, 119]. Omalizumab, an anti-IgE monoclonal antibody, demonstrated positive results in improving skin symptoms of patients with CPG in a small cohort study [120]. Rocatinlimab, a human monoclonal antibody targeting OX40, a co-stimulatory T cell receptor, improved pruritus scores in patients with AD, and its efficacy in treating CPG was tested in a phase III RCT [121]. However, the development of rocatinlimab has been recently discontinued following safety concerns identified during clinical studies, including a possible increased risk of malignancy, particularly Kaposi sarcoma [122]. Barzolvolimab, a anti-KIT monoclonal antibody, is currently in a phase II RCT to assess its efficacy and safety in adults with CPG. Previous data showed promising results, with a 46% mean reduction in the WI-NRS scores after 8 weeks of treatment [123]. Limitations Several limitations should be considered when interpreting these consensus recommendations. Members of the scientific committee participated in the Delphi panel, which may introduce bias. Nevertheless, anonymized voting and aggregated analysis were implemented to mitigate this risk. Some authors have financial relationships with companies producing therapies discussed in this manuscript, which may represent a potential conflict of interest. Key limitations include heterogeneity of CPG definitions across studies, frequent reliance on retrospective or administrative datasets, and limited head-to-head or long-term comparative evidence for several emerging therapies. Therefore, some recommendations are conditional and should be individualized according to individual phenotype, comorbidities, and local regulatory access. Conclusions The recommendations stated in this document provide practical guidance for the management of CPG. Diagnosis is based on the presence of three criteria: a ≥ 6-week history of pruritus; a history of repeated excoriation; and the presence of skin lesions (including nodules, papules, umbilicated lesions, and/or linear lesions). Diagnosis should be based on the patient’s anamnesis and physical examination, and complemented with laboratory tests or other exams if needed. Therapy should follow a personalized protocol, guided by disease severity, using both clinician- and patient-reported outcomes. Topical therapies should complement systemic therapies. Systemic treatments for eligible patients include CPG-approved biological agents (dupilumab and nemolizumab), gabapentinoids, and antidepressants. JAK inhibitors, opioid receptor modulators, methotrexate, and cyclosporine are additional treatment options that may be considered. Treatment efficacy should be assessed to ensure meaningful clinical improvement and patient adherence. These recommendations reflect the collective expertise of the Delphi panel dermatologists in routine clinical practice, providing practical, consensus-based guidance for clinicians managing patients with CPG in real-world settings. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 186 KB) Acknowledgements Delphi panel participants: Ana Brasileiro, Unidade Local de Saúde de São José, Lisboa, Portugal; Ana Carolina Figueiredo, Unidade Local de Saúde de Coimbra, Coimbra, Portugal; André Lencastre, Hospital de Cascais Dr. José de Almeida, Cascais, Portugal; Ângela Roda, Unidade Local de Saúde de Almada Seixal, Almada, Portugal; Bárbara Roque Ferreira, Unidade Local de Saúde do Algarve, Faro, Portugal; Bruno Duarte, Unidade Local de Saúde de São José, Lisboa, Portugal; Catarina Queirós, Unidade Local de Saúde de Braga, Braga, Portugal; Cristina Amaro, Unidade Local de Lisboa Ocidental, Lisboa, Portugal; Fernando Mota, Unidade Local de Saúde do Alto Ave, Guimarães, Portugal; Joana Antunes, Unidade Local de Saúde de Santa Maria, Lisboa, Portugal; Joel Reis, Unidade Local de Saúde de Matosinhos, Matosinhos, Portugal; Leonor Ramos, Unidade Local de Saúde de Coimbra, Coimbra, Portugal; Margarida Rato, Casa de Saúde de São Mateus, Viseu, Portugal; Maria João Cruz, Unidade Local de Saúde de São João, Porto, Portugal; Martinha Henrique, Unidade Local de Saúde de Leiria, Leiria, Portugal; Nuno Preto Gomes, Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal; Paulo Varela, Unidade Local de Saúde de Gaia e Espinho, Vila Nova de Gaia, Portugal; Sandra Medeiros, Clínica do Colégio, Ponta Delgada, Açores, Portugal. Springer Healthcare is not responsible for the validity of guidelines it publishes. Medical Writing/Editorial Assistance The authors would like to thank Raquel Duarte, PhD of X2 – Science Solutions, for medical writing, editorial, and submission support, and for the external moderation of the Delphi process. The moderator coordinated the Delphi rounds, provided fully anonymized and analyzed results, had no role in study design or interpretation, and does not hold financial relationships with any of the companies producing therapies for chronic prurigo. Medical writing, editorial, and submission support was funded by Sociedade Portuguesa de Dermatologia e Venereologia (SPDV), Sanofi, and Galderma. Author Contributions Inês Lobo, Gilberto Pires da Rocha, Margarida Gonçalo, Pedro Mendes-Bastos, Rita Pimenta: Conception of the work, members of Delphi panel, critical review, and approval of the final version to be published. Funding This study was supported by SPDV, Sanofi, and Galderma. SPDV, Sanofi and Galderma had no influence on the Delphi panel, interpretation of the data, or content of the manuscript. The journal’s Rapid Service Fee was covered by SPDV. Data Availability Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Declarations Conflict of Interest Gilberto Pires da Rocha has received honoraria for acting as a speaker for Leo-Pharma, Sanofi, and L’Oreal. Inês Lobo participated in advisory boards and/or speakers bureau from AbbVie, Novartis, Beiersdorf. Inês Lobo has served as principal investigator in clinical trials and/or observational studies supported by AbbVie, Sanofi, Novartis and MoonLake Immunotherapeutics. Margarida Gonçalo participated in advisory boards and/or speakers bureau from AbbVie, Almirall, Astrazeneca, Biocryst, Leo-Pharma, Novartis, Pfizer, Sanofi-Genzyme, and Takeda. Pedro Mendes-Bastos has received honoraria for acting as a consultant and/or as a speaker for Almirall, Alumis, Apogee, AbbVie, Pfizer, Johnson & Johnson Innovative Medicine, Leo-Pharma, GlaxoSmithKline, Novartis, Eli Lilly, Sanofi, Regeneron, L’Oreal, Pierre Fabre, Viatris, Organon, Evelo Biosciences, CS Labs, and Takeda; Pedro Mendes-Bastos has served as principal investigator in clinical trials supported by AbbVie, Alumis, Amgen, Biogen, Johnson & Johnson Innovative Medicine, Pfizer, Novartis, Sanofi, and Sanofi-Regeneron. Rita Pimenta has received honoraria for acting as a consultant and/or speaker for AbbVie, Almirall, Leo-Pharma, LETI Pharma, and Novartis and served as principal investigator in clinical trials and/or observational studies supported by AbbVie, Almirall, Johnson & Johnson Innovative Medicine, and Novartis. Ethical Approval This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The Delphi panel reflects only the opinions of participating experts who voluntarily completed the questionnaire. Consequently, ethical review or formal approval was not required. Participation in the Delphi panel was entirely voluntary and fully anonymized, and all participants provided informed consent regarding the handling and protection of their personal data prior to participation. Footnotes Delphi panel participants are listed in the Acknowledgements section. The original online version of this article was revised: Text corrections updated. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Change history 8/11/2026 A Correction to this paper has been published: 10.1007/s13555-026-01877-w References Associated Data Supplementary Materials Supplementary file1 (PDF 186 KB) Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.